Related Experiment Video
Updated: Sep 27, 2026
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Prognostic factors for chronic active Epstein-Barr virus infection
Hiroshi Kimura1, Tsuneo Morishima, Hirokazu Kanegane
1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. hkimura@med.nagoya-u.ac.jp
Insights
Prognostic factors for chronic active Epstein-Barr virus infection (CAEBV) were identified. Older age, thrombocytopenia, and T cell infection are associated with poorer survival outcomes in CAEBV patients.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Chronic active Epstein-Barr virus infection (CAEBV) is a severe condition with high mortality and morbidity.
- Identifying prognostic factors is crucial for managing CAEBV patients.
Purpose of the Study:
- To analyze prognostic factors influencing survival in patients diagnosed with CAEBV.
- To determine key indicators for predicting outcomes in CAEBV.
Main Methods:
- A national survey in Japan analyzed data from 82 patients meeting CAEBV criteria.
- Multivariate analysis was employed to identify correlations with mortality.
Main Results:
- Thrombocytopenia (platelet count < 12 x 10(4)/microL) and older age at onset (≥ 8 years) were significantly correlated with increased mortality.
- Patients with T cell infection by EBV had shorter survival times compared to those with natural killer cell infection (5-year survival: 0.59 vs. 0.87).
- Five-year survival rates were 0.45 for older patients and 0.38 for those with thrombocytopenia.
Conclusions:
- Late onset of disease, thrombocytopenia, and T cell involvement are significant indicators of poorer outcomes in CAEBV.
- These findings aid in risk stratification and clinical management of CAEBV.
Abstract:
Chronic active Epstein-Barr virus infection (CAEBV) is a high-mortality and high-morbidity disease. To clarify the prognostic factors, a national survey was performed in Japan, and data for 82 patients who met the criteria for CAEBV were analyzed. Of these 82 patients, 47 were alive and 35 had already died. Multivariate analysis revealed that thromobocytopenia and age at disease onset were correlated with mortality. The probability of 5-year survival was 0.45 for older patients (onset age, > or = 8 years), 0.94 for younger patients (P<.001), 0.38 for patients with thrombocytopenia (platelet count < 12 x 10(4) platelets/microL at diagnosis), and 0.76 for patients without thrombocytopenia (P=.01). Furthermore, patients with T cell infection by EBV had shorter survival times than patients with natural killer cell infection (probability of 5-year survival, 0.59 vs. 0.87; P<.009). Patients with CAEBV with late onset of disease, thrombocytopenia, and T cell infection had significantly poorer outcomes.
